Dybly develops pharmaceutical products for patients affected by the build-up of atherosclerotic plaques.

Dybly is active with three projects:

DYB186
Stimulate body‘s own ability to reduce the cholesterol content of plaques and prevent infarction with a chronic oral treatment

DYB286
Prevent MI with a novel form of a proven antiplatelet

DYB143
First-ever targeted treatment to block tightening effect of plaques and avoid leg cramps, enabling patients to regain a more mobile lifestyle

*  Diagnosis: Intermittent Claudication, PA(O)D Fontaine stage II

**  Diagnosis: Infarction (Heart = MI, Brain = Stroke, Leg infarction)